Recommendations for the clinical use of anti-amyloid-β monoclonal antibody for Alzheimer's disease(2025)
- VernacularTitle:抗Aβ单克隆抗体临床应用建议(2025版)
- Author:
Nan ZHI
1
;
Jinwen XIAO
;
Rujing REN
;
Binyin LI
;
Jintao WANG
;
Jieli GENG
;
Wenwei CAO
;
Yaying SONG
;
Hualong WANG
;
Shuguang CHU
;
Guoping PENG
;
Jun LIU
;
Xiaoyun LIU
;
Fang YUAN
;
Wen WANG
;
Ronghua DOU
;
Xia LI
;
Ling YUE
;
Wenshi WEI
;
Xiaoling PAN
;
Xiangyang ZHU
;
Dian HE
;
Weinü FAN
;
Jingping SHI
;
Nan ZHANG
;
Hui ZHAO
;
Qin CHEN
;
Cuibai WEI
;
Xiaochun CHEN
;
Gang WANG
Author Information
- Keywords: Alzheimer's disease; β-amyloid; monoclonal antibodies; clinical practice recommendations
- From: Journal of Chongqing Medical University 2025;50(9):1133-1140
- CountryChina
- Language:Chinese
- Abstract: In recent years,significant breakthroughs have been achieved in the immunotherapy for Alzheimer's disease.In line with global advancements,two anti-amyloid-β monoclonal antibodies have been approved and successfully launched in China for clinical use.Lecanemab and Donanemab were officially used in June 2024 and April 2025 in China,respectively.In order to standardize the rational and safe application of anti-amyloid-β monoclonal antibodies for Alzheimer's disease in China,this article integrates recom-mendations from the clinical trials and real-world experience from the author's team and domestic peers to further update the recom-mendations for the clinical use of anti-amyloid-β monoclonal antibody based on the 2024 version.It includes indications for therapy,pre-treatment evaluation and preparation,administration protocols and safety measures during treatment,and post-treatment monitor-ing strategies.
